The US FDA has approved zenocutuzumab for treating adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) harboring a neuregulin 1 gene fusion with disease progression on or after systemic therapy. Zenocutuzumab, a bispecific HER2- and HER3-directed antibody, is available as a single-dose vial for intravenous use. Clinical evidence The safety and efficacy of zenocutuzumab were evaluated in clinical trials involving 64 NSCLC patients and 30 pancreatic adenocarcinoma patients.
The drug achieved 33% and 40% of overall response rates in NSCLC and pancreatic adenocarcinoma patients, respectively. Furthermore, the duration of response was 7.4 months for NSCLC patients and ranged from 3.7 to 16.6 months for pancreatic adenocarcinoma patients. Dosage and administration Assess left ventricular ejection fraction before initiation 750 mg…
